| 13.48 0.28 (2.12%) | 07-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.03 |
1-year : | 18.72 |
| Resists | First : | 13.72 |
Second : | 16.03 |
| Pivot price | 12.34 |
|||
| Supports | First : | 11.54 |
Second : | 10.19 |
| MAs | MA(5) : | 13.02 |
MA(20) : | 12.06 |
| MA(100) : | 10.52 |
MA(250) : | 10.46 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 92.1 |
D(3) : | 87.2 |
| RSI | RSI(14): 69.9 |
|||
| 52-week | High : | 13.72 | Low : | 8.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DCTH ] has closed below upper band by 4.1%. Bollinger Bands are 57.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 13.74 - 13.79 | 13.79 - 13.85 |
| Low: | 12.92 - 12.98 | 12.98 - 13.04 |
| Close: | 13.38 - 13.47 | 13.47 - 13.57 |
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Sat, 04 Jul 2026
DCTH - Delcath Systems Inc Options - Finviz
Wed, 01 Jul 2026
Price to sales forward of Delcath Systems, Inc. – NASDAQ:DCTH - TradingView
Mon, 29 Jun 2026
Delcath Systems, Inc.(NasdaqCM: DCTH) added to Russell 2000 Value Benchmark - marketscreener.com
Sun, 28 Jun 2026
Delcath Systems, Inc.(NasdaqCM: DCTH) added to Russell 3000 Value Benchmark - marketscreener.com
Thu, 25 Jun 2026
DCTH Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 28 May 2026
DCTH - Delcath Systems Inc Stock Price and Quote - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 35 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 8.1 (%) |
| Held by Institutions | 48.9 (%) |
| Shares Short | 3,300 (K) |
| Shares Short P.Month | 3,430 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.26 |
| Profit Margin | 0.6 % |
| Operating Margin | -6.6 % |
| Return on Assets (ttm) | -1 % |
| Return on Equity (ttm) | 0.5 % |
| Qtrly Rev. Growth | 26.2 % |
| Gross Profit (p.s.) | 2.25 |
| Sales Per Share | 2.61 |
| EBITDA (p.s.) | -0.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 21 (M) |
| Levered Free Cash Flow | 20 (M) |
| PE Ratio | 1348 |
| PEG Ratio | 1.6 |
| Price to Book value | 4.12 |
| Price to Sales | 5.14 |
| Price to Cash Flow | 21.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|